Phase II, Open-label, Parallel 2-arm, Multi-center
1 clinical trials · Condition
◉ Watch Phase II, Open-label, Parallel 2-arm, Multi-center
| Record | Firm | Date |
|---|---|---|
| A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer (NCT05026905) | National Health Research Institutes, Taiwan | 2021-12-28 |
Track Phase II, Open-label, Parallel 2-arm, Multi-center automatically
Every clearance here is in the API, with alerts when new ones post.